Not yet a member?

Registered users have the ability to access exclusive content and features for logged in users only. Join our community in one click.

Registration

First name Please enter your first name Last name Please enter your last name

Email address Please enter Email address

Country

Austria
Belgium
Canada
Denmark
Finland
France
Germany
Ireland
Italy
Japan
Luxembourg
Netherlands
Norway
Portugal
Rest of the World
Singapore
Slovakia
South Korea
Spain
Sweden
Switzerland
United Kingdom
USA

Language

Profile Please enter your profile

Terms and conditions

Please check this box if you want to proceed

You already have an account? Login

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

About this author

Malgorzata Kluba, PhD

Senior Biotechnology Analyst

Download a photo

Malgorzata Kluba has been a Senior Biotechnology Analyst at Candriam since 2019.

Before joining Candriam Malgorzata spent four years as an R&D scientist at ActoBio Therapeutics (Intrexon Actobiotics) in Belgium – a synthetic biology company where she had been working on novel drug delivery platform. She has also worked as a journalist for a life sciences communication agency (BioVox / Tunstone Communications), focusing on Belgian biotechnology market.

Malgorzata holds PhD degree in biochemistry and biotechnology from University of Leuven, Belgium, where she researched cancer signalling pathways.

Discover the latest articles by Malgorzata Kluba, PhD

04 FEB 2023

Malgorzata Kluba, Rudi Van Den Eynde, Oncology, Equities

World Cancer Day 2023

And we would rather not have to go through this – which would mean we won the battle and cancer is curable.

Malgorzata Kluba